Statin therapy in renal disease: Harmful or protective?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Chronic kidney disease (CKD) creates one of the highest-risk atherosclerotic states that can occur in human beings. The use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has gained widespread acceptance in the general population for the purposes of lowering low-density lipoprotein cholesterol (LDL-C) and reducing the future risks of myocardial infarction, stroke, and cardiac death. In patients with CKD, these benefits are believed to be enjoyed to the same or greater degrees. Reductions in LDL-C with statins may be associated with a reduced progression of CKD. Importantly, recent studies suggest statins are associated with a reduction in rates of acute renal failure after cardiopulmonary bypass surgery and exposure to iodinated contrast. In patients with end-stage renal disease (ESRD), recent data suggest that the annual rate of coronary artery calcification can be attenuated or reduced with LDL-C reduction. However, two large trials demonstrating LDL-C reduction with statins and with these drugs have failed to demonstrate a reduction in cardiovascular events in ESRD. Thus, the potential benefits of statins and LDL-C reduction in CKD have to be considered in light of evidence suggesting a reduced benefit, if any, in patients with ESRD. In addition, studies suggest that there are higher adverse drug effects with statins in CKD.
- Yerkey MW, Kernis SJ, Franklin BA, et al.: Renal dysfunction and acceleration of coronary disease. Heart 2004, 90:961–966. CrossRef
- McCullough PA: Why is chronic kidney disease the “spoiler” for cardiovascular outcomes? J Am Coll Cardiol 2003, 41:725–728. CrossRef
- McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens 2004, 13:591–600. CrossRef
- Bakker SJ, Gansevoort RT, Stuveling EM, et al.: Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk? Curr Hypertens Rep 2005, 7:379–384. CrossRef
- Clerico A, Recchia FA, Passino C, Emdin M: Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17–H29. CrossRef
- de Jong PE, Gansevoort RT: Screening techniques for detecting chronic kidney disease. Curr Opin Nephrol Hypertens 2005, 14:567–572. CrossRef
- McCullough PA, Lepor NE: Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005, 6(Suppl 3):4–12.
- McCullough PA, Brown WW, McGill JB, et al.: for the KEEP Investigators: Independent components of chronic kidney disease as a cardiovascular risk factor; results from the Kidney Early Evaluation Program (KEEP). J Am Coll Cardiol 2005, 45:424A. CrossRef
- National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Diseases. Executive Summary. New York: 2003.
- Grundy SM, Cleeman JI, Merz CN, et al., for the National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239. Review. Erratum in Circulation 2004, 110:763. CrossRef
- Landray M, Baigent C, Leaper C, et al.: The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006, 47:385–395. CrossRef
- Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260–269. CrossRef
- Vidt DG, Harris S, McTaggart F, et al.: Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006, 97:1602–1606. CrossRef
- Park JK, Muller DN, Mervaala EM, et al.: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure and cholesterol lowering effects. Kidney Int 2000, 58:1420–1430. CrossRef
- Lazar HL, Bao Y, Zhang Y, et al.: Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 2003, 125:1037–1042. CrossRef
- Asimakopoulos G: Systemic inflammation and cardiac surgery: an update. Perfusion 2001, 16:353–360.
- Paparella D, Yau TM, Young E: Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002, 21232–21244.
- Rinder CS, Fontes M, Mathew JP, et al.; Multicenter Study of Perioperative Research Group: Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. Ann Thorac Surg 2003, 75:899–905. CrossRef
- Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concept for cardiovascular disease. Cardiovasc Res 2001, 49:281–287. CrossRef
- Chello M, Mastroroberto P, Patti G, et al.: Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003, 89:538–543. CrossRef
- Kinlay S, Schwartz GG, Olsson AG, et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560–1566. CrossRef
- Chello M, Barbato R, Patti G, et al.: Prevention of postoperative acute renal failure by statin therapy in patients undergoing cardiac surgery. J Am Coll Cardiol 2006, In press.
- Khanal S, Attallah N, Smith DE, et al.: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005, 118:843–849. CrossRef
- Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990, 11(Suppl E):3–19.
- Bostrom K, Watson KE, Horn S, et al.: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993, 91:1800–1809. CrossRef
- Tanimura A, McGregor DH, Anderson HC: Calcification in atherosclerosis, I: human studies. J Exp Pathol 1986, 2:261–273.
- Tanimura A, McGregor DH, Anderson HC: Calcification in atherosclerosis, II: animal studies. J Exp Pathol 1986, 2:275–297.
- Simons DB, Schwartz RS, Edwards WD, et al.: Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: a quantitative pathologic comparison study. J Am Coll Cardiol 1992, 20:1118–1126. CrossRef
- McCullough PA, Soman S: Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int Suppl 2004, 90:S18–S24. CrossRef
- Achenbach S, Ropers D, Pohle K, et al.: Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002, 106:1077–1082. CrossRef
- Callister TQ, Raggi P, Cooil B, et al.: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998, 339:1972–1978. CrossRef
- Nissen SE, Tuzcu EM, Schoenhagen P, et al., for the REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080. CrossRef
- McCullough PA, Soman SS, Shah SS, et al.: Risks associated with renal dysfunction in coronary care unit patients. J Am Coll Cardiol 2000, 36:679–684. CrossRef
- Shlipak MG, Fried LF, Crump C, et al.: Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002, 62:997–1004. CrossRef
- Schoenhagen P, Tuzcu EM: Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clin J Med 2002, 69(Suppl 3):S12–S20.
- Reslerova M, Moe SM: Vascular calcification in dialysis patients: pathogenesis and consequences. Am J Kidney Dis 2003, 41:S96–S99.
- McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004, 17:205–215.
- Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002, 62:245–252. CrossRef
- Suki W, Zabaneh R, Cangiano J, et al.: The DCOR trial—a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. American Society of Nephrology Renal Week 2005. November 8–13, 2005; Philadelphia. Abstract PO745.
- Wanner C, Krane V, Marz W, et al.: for the German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248. [Published erratum appears in N Engl J Med 2005, 353:1640.] CrossRef
- Stern RH, Yang BB, Horton M, et al.: Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997, 37:816–819.
- Halstenson CE, Triscari J, DeVault A, et al.: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impariment. J Clin Pharmacol 1992, 32:124–132.
- Gehr TW, Sica DA, Slugg PH, et al.: The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997, 53:117–121. CrossRef
- Quérin S, Lambert R, Cusson JR, et al.: Single-dose pharmacokinetics of 14C-lovastatin in chronic renal failure. Clin Pharmacol Ther 1991, 50:437–441. CrossRef
- Kasiske BL, Wanner C, O’Neill WC; National Lipid Association Statin Safety Task Force Kidney Expert Panel: An assessment of statin safety by nephrologists. Am J Cardiol 2006, 97:82C–85C. CrossRef
- Verhulst A, D’Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249–2257. CrossRef
- Sidaway JE, Davidson RG, McTaggart F, et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258–2265. CrossRef
- Douglas K, O’Malley PG, Jackson JL: Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117–124.
- Statin therapy in renal disease: Harmful or protective?
Current Diabetes Reports
Volume 7, Issue 6 , pp 467-473
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links